synthetic lethality

Glowing puzzle piece fitting into puzzle

Biotech

Boehringer slots synthetic lethal program into oncology pipeline

Boehringer has partnered with Tessellate Bio on a synthetic lethal program in a deal worth more than 500 million euros in biobucks.

Nick Paul Taylor Apr 23, 2025 7:45am

team layoffs workforce

Zentalis lays off 40% to fund registrational trial of WEE1 drug

Jan 29, 2025 4:42am

pay deal hand over cash licensing transaction money

BeiGene inks $150M deal to follow cancer trail blazed by Amgen

Dec 13, 2024 9:11am

tango dance partner

Tango axes PRMT5 inhibitor, shifts focus to 2 sibling molecules

Nov 6, 2024 8:28am

Layoffs

Repare lays off 25% of staff as biotech halts preclinical R&D

Aug 29, 2024 6:36am

MA strategy deal block push come together form

Ideaya bags option on Biocytogen bispecific ADC in $400M deal

Jul 31, 2024 9:04am